TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...
T-cell engagers (TCEs) drive synthetic antitumor immunity by bypassing endogenous T-cell priming and directly inducing tumor cell killing. In prostate cancer, targeting prostate-restricted antigens ...
Intralesional nivolumab appeared effective for treating precancerous oral lesions in a phase 1, open-label, dose-escalation trial.
Kidney damage is a serious complication affecting individuals with lupus, an autoimmune disease where immune B cells ...
T-cell therapy is one of oncology's most powerful ideas: Harvest a cancer patient's own immune cells, genetically engineer ...
T-cell profiles derived from blood and renal biopsy may be novel biomarkers of lupus nephritis treatment response, study findings suggest.
Children's Hospital of Philadelphia Pathology and Laboratory Medicine researchers uncovered how killer T cells – called CD8+ T cells – keep fighting inside tumors, where nutrients are scarce and ...
Barbara Burtness, MD, discusses the latest highlights from the AACR Annual Meeting 2026 that took place April 17-22.
Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic ...
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results